These results underscore the dual role of CYP2E1-mediated ROS generation and immune-mediated liver sensitivity, and support the hypothesis that CYP2E1 is a key contributor to the hepatotoxic potential of AT drugs, especially in the presence of coexisting inflammation [106]. Here, CYP2E1 is linked to ataxia telangiectasia.